J Cancer 2020; 11(6):1596-1605. doi:10.7150/jca.38217 This issue Cite
Research Paper
1. Department of Oral Maxillofacial-Head and Neck Oncology, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, No 639, Zhizaoju Rd, Shanghai 200011, China
2. National Clinical Research Center for Oral Diseases, Shanghai 200011, China.
3. Shanghai Key Laboratory of Stomatology & Shanghai Research Institute of Stomatology, Shanghai 200011, China.
4. Key Laboratory of Oral Medicine, Guangzhou Institute of Oral Disease, Stomatology Hospital of Guangzhou Medical University, Guangzhou, 510140, China.
#Qiaoshi Xu and Hanyue Chang contributed equally to this work.
Objective: Microfibrillar-associated protein 5 (MFAP5) is highly expressed in many types of cancers. Our previous study has observed that overexpression of MFAP5 was correlated with lymph nodes metastasis and poor prognosis in head and neck squamous cell carcinoma (HNSCC), but the underlying mechanism is poorly understood.
Materials and methods: The MFAP5 expression is detected under hypoxia condition. HNSCC cell lines are transfected with MFAP5-expressing lentivirus vector to establish stable overexpression model. Wound-healing, migration and invasion assay are used to determine the effect of MFAP5 on HNSCC and metastasis-related proteins are examined by Western blot. In vivo lung metastasis assays are conducted by the tail vein injection. In addition, immunohistochemistry is applied to analyze the correlation of MFAP5, hypoxia-induced factor-1 α (HIF-1α), and vimentin in 84 HNSCC patients' tissue samples.
Results: Firstly, MFAP5 expression can be markedly induced under hypoxia condition in HNSCC cell lines. Cell lines with MFAP5 overexpression has a significant higher ability of migration and invasion. In addition, in vivo assay observes that overexpression of MFAP5 can promote tumor lung metastasis. Furthermore, MFAP5 facilitates this process by activating epithelial-mesenchymal transition (EMT) program via AKT pathway in HNSCC cell lines. The pro-metastatic effect of MFAP5 can be reversed by MK2206, an AKT phosphorylation inhibitor. Lastly, the positive correlation among HIF-1α, MFAP5 and vimentin from tissue samples and TCGA dataset are also observed in HNSCC.
Conclusion: Our study demonstrates MFAP5 plays a critical role in hypoxia-induced EMT program via AKT pathway in HNSCC, which would be a very promising therapeutic target.
Keywords: Microfibrillar-associated protein 5, Head and neck squamous cell carcinoma, Migration, Invasion, AKT
Head and neck squamous cell carcinoma (HNSCC) is one of the most common cancers and affects more than 600,000 patients per year [1]. Despite large advances in cancer treatment strategies, the long-term survival of HNSCC patients remain poor. According to recent studies, tumor recurrence and metastasis are the major causes of death among cancer patients [2-4]. The study on mechanisms of invasion and metastasis of tumor cells receive more and more considerations.
Microfibrillar-associated protein 5 (MFAP5), as known as Microfibril-associated glycoprotein 2 (MAGP2), has an important role in building microfibril networks and forming vascular structure [5-7]. It has been proven as an oncogene in many types of cancers [8-10]. Mok et al. claimed that MFAP5 can prolong tumor cell survival and stimulate endothelial cell motility in ovarian cancer [11]; Li et al. demonstrated that knockdown MFAP5 can markedly reduce the cell proliferation, migration and invasion depend on ROS production in cervical cancer [12]. Other studies showed MFAP5 has obvious impact on epithelial-mesenchymal transition (EMT) progression [13, 14]. In our previous study, we have observed that MFAP5 was overexpression in HNSCC and correlated with lymph nodes metastasis and poor prognosis [15]. However, the biologic function and underlying mechanism of MFAP5 in HNSCC is lack of study.
Hypoxia is a common situation in many solid tumors and has been considered as a key part in tumor progression [16]. Hypoxia-inducible factor-1α (HIF-1α), the direct responder of hypoxia, is related with poor prognosis and highly expressed in metastasis tumor [17]. Accumulative evidences showed that hypoxia can initiate EMT progression via HIF-1α [18, 19]. Interestingly, although both being a cancer-promoting factor, the relationship between hypoxia and MFAP5 is rarely explored. Moreover, MFAP5 is believed to be secreted mainly by tumor stroma cells [20]. Whether MFAP5 can play a crucial role in hypoxia-induced EMT progression is still obscure.
In the present study, we found that hypoxia condition could induce MFAP5 expression by HNSCC cells which indicated that tumor cells are also an important resource of MFAP5. A series experiments demonstrated that MFAP5 promote tumor migration and invasion of HNSCC both in vitro and in vivo through AKT pathway. Overexpression of MFAP5 significantly correlated with advanced clinical stage, metastasis and poor prognosis of HNSCC patients. Our findings not only suggested that hypoxia environment could stimulate tumor cell to secret MFAP5 but also proved that MFAP5 promotes EMT program in HNSCC. These findings show the critical role of MFAP5 in hypoxia induced tumor progression, which would be a very promising therapeutic target.
This study was conducted in full accordance with ethical principles, and approved by the Medical Ethics Committee of the Ninth People's Hospital, Shanghai Jiao Tong University, School of Medicine. Patients' inclusion criteria included the following: (1) patients with a pathological diagnosis of squamous cell carcinoma; (2) patients who were primarily treated with surgery; (3) patients with no previous treatment; (4) patients with complete clinicopathological data and available tissue specimens. The exclusion criteria included preoperative chemotherapy or radiotherapy, failure to undergo surgery and the inability to obtain pathological slices. From January 2007 to December 2008, a total of 84 HNSCC patients were met the inclusion criteria. The tissue samples and medical records of patients enrolled were collected by strict procedures.
The cell lines used in this study were Cal27 and HN30. Cal27 were purchased from ATCC (Manassas, VA). The cell lines HN30 was established from pharyngeal squamous cell carcinoma and were kindly provided by the University of Maryland Dental School, USA. All these cell lines were cultured in Dulbecco's modified Eagle's medium (DMEM) (Gibco, Carlsbad, CA) supplemented with 10% fetal bovine serum, 1% glutamine, and 1% penicillin-streptomycin. Cells were cultured in a standard humidified atmosphere of 5% CO2 at 37 °C in general and in hypoxia cell incubator (ESCO, Singapore) at 2% O2 for hypoxia experiment.
The tissue samples of enrolled patients were examined for the expression of MFAP5, HIF-1α and vimentin by immunohistochemical staining. The staining followed the standard protocol. Briefly, paraffin-embedded sections were heated by water bath at 100 °C with citrate buffer solution (pH 6.0) for 20 minutes to retrieve antigen, and were cooled at room temperature. The primary antibodies were monoclonal antibody against MFAP5 (ab203828, Abcam, USA), HIF-1α (ab113642, Abcam, USA) and vimentin (D21H3, Cell signaling technology, USA) and were incubated overnight at 4 °C, then visualized using 3,3'-diaminobenzidine (DAB) detection kit (Dako Cytomation, Denmark) containing goat secondary antibody molecules and DAB chromogen. Every step of the wash used phosphate buffered saline solution (PBS) for 5 minutes three times. The intensity of the MFAP5, HIF-1α and vimentin immunoreaction was scored as following: 0 = negative, absence of stained cells; 1 = weak; 2 = moderate; 3 = strong. The immunohistochemical staining score was calculated by multiplying the percentage of positive cells and the staining intensity as described in the literature.
For gene overexpression, lentivectors containing MFAP5 sequence or control lentivectors (Genomeditech, Shanghai, China) were transfected into Cal27 and HN30 cells according to the manufacturer's instruction. The transfected cells were treated with puromycin (5 μg/mL) for 2 weeks to establish stable cell lines.
For transwell assays, 2~10×104 transfected cells were seeded in the upper chambers of filter inserts containing serum-free medium. The chambers without matrigel were used to detect cell migration ability while the one with matrigel to analyze cell invasion. 500 μl medium containing 10% FBS were held in the lower chambers in 24-well plates. After incubation of 48 h, the cells migrated through the membrane were fixed, stained with 5% crystal violet. The number of cells and photographs were counted and taken with a Nikon DMCI microscope (Nikon, Tokyo, Japan).
Briefly, transfected cells were seeded in a 6-well plate overnight and yielding confluent monolayers suitable for wounding. The wounds were scratched by a 10 μl pipette tip and photographs were taken at 0 h and 24 h. The width of wound was measured to assess the migration ability of cells.
Total RNA was extracted from cultured cells with Trizol Reagent (Invitrogen) following the manufacturer's protocol. RNA was reversely transcribed to cDNA using the SYBR Premix Ex Taq reagent kit (Takara, Japan). Real-time PCR (qRT-PCR) was performed using a StepOnePlus Real-time PCR system (Thermo Fisher, Waltham, MA, USA) using the following specific primers: MFAP5: forward: 5′-TGGCTGATATTGCACCTTCCAC-3' and reverse: 5′-ATTTCTCATCCCAGCACTCTGC-3'; GAPDH forward: 5′-CCTCTGACTTCAACAGCGAC-3′ and reverse: 5′-TCCTCTTGTGCTCTTGCTGGC-3′.
Western blot assay was performed using the standard method as briefly described [21,22]. Protein samples were collected after cells were lysed and quantified. 20~30 μg/lane protein were separated by 10%~15% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). A wet transfer (Bio-Rad, USA) were then performed to transfer the protein onto polyvinylidene fluoride (PVDF) membranes and blocked with non-fat milk for 1 h. The membranes were incubated with primary antibody MFAP5 (HPA010553,Sigma,Germany), MMP9 (D6O3H, Cell signaling technology, USA), MMP2 (D4M2N Cell signaling technology, USA), vimentin (D21H3, Cell signaling technology, USA), Sanil (C15D3, Cell signaling technology, USA), AKT (11E7, Cell signaling technology, USA), p-AKT (D9E, Cell signaling technology, USA), HIF-1α (D1S7W, Cell signaling technology, USA), α-tubulin (11224, Proteintech, USA), β-actin (20536 Proteintech, USA) at 1:1000 dilution overnight and then with anti-rabbit HRP-linked IgG secondary antibody(7074, Cell signaling technology, USA) at 1:2000 dilution for 1 hour. The immunoreactive bands were visualized with ECL Ultra (New Cell and Molecular Biotech, Suzhou, China). α-tubulin and β-Actin was used as an internal control.
6-week-old BALB/c nude mice purchased from the Shanghai Laboratory Animal Center (Shanghai, China) were bred in SPF facilities. 1×106 Cal27 cells transfected with luciferase-expressed lentivirus containing MFAP5 sequence or control lentivectors were injected into mice through lateral tail vein. Lung metastasis was monitored using bioluminescence imaging (BLI) by IVIS Imaging System once a week [23]. The mice were killed at 5 weeks and the lung tissues were fixed and stained before microscopic analysis. The in vivo studies were approved by the Animal Care and Use Committee of Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine.
Statistical analysis was performed using SPSS 13.0 for Windows (SPSS Inc., Chicago, IL) and GraphPad Prism version 6 (GraphPad Software, San Diego, CA, USA) was used to plot the data. Student's t test and chi-square test was performed to assess the statistical significance of differences. Survival analysis was conducted using the Kaplan-Meier method and log-rank test. P < 0.05 was considered statistically significant (* P < 0.05, and ** P < 0.01). All values are expressed as the means ± standard error.
To testify the relationship between hypoxia and MFAP5 in HNSCC, we cultured the HNSCC cells in hypoxia environment for 1 h and 10 h, and compared the MFAP5 level by western blot. The result showed that MFAP5 expression was significant higher in hypoxia environment (Figure 1A, P<0.01), along with HIF-1α (Figure 1A, P<0.01), which indicated that hypoxia environment enhances the expression of MFAP5 in HNSCC. This conclusion has been verified in patients' tissue samples. The expression level of MFAP5 and HIF-1α was remarkably correlated in same tumor species (Figure 1B, 1C, r=0.493, P<0.01).
Interestingly, we found the expression of snail was also accord with MFAP5 (Figure 1A, P<0.01). As a key promotor of EMT progression, this result reminded us that MFAP5 might promote the expression of EMT phenotypic protein by activate snail, thus leading to tumor metastasis.
Hypoxia induces MFAP5 expression in HNSCC. (A) The protein level of HIF-1α, snail and MFAP5 in hypoxia environment for 0h, 1h and 10h. β-actin was used as an internal control. The proteins level is significant higher in hypoxia environment (**P<0.01). (B) The expression level of MFAP5 and HIF-1α is related in same tumor. (C) The correlation analysis of immunohistochemistry intensity for HIF-1α and MFAP5 in 84 patients' tissue sample (r=0.493, **P<0.01).
To detect the function of MFAP5 in HNSCC, we transfected the MFAP5 lentivirus into Cal27 and HN30 cell lines and the result of PCR confirmed the transfection efficiency (P<0.01, Figure 2A). Transwell migration assay showed that overexpressed of MFAP5 markedly enhanced the motility of HNSCC cells (P<0.01, Figure 2B). The scratch wound healing assay confirmed this result. Cells transfected with MFAP5 lentivirus had a significant higher migration ability (P <0.01, Figure 2C). As a key parameter of metastasis, the cell invasion ability was assessed by transwell invasion assay. The result showed that cell invasion was enhanced by MFAP5 compared with control group (P <0.01, Figure 2D). The results above indicated that MFAP5 could promote migration and invasion in HNSCC cell lines.
To examine the effect of MFAP5 on lung metastasis in vivo, we injected 1×106 Cal27-MFAP5 into 6-week-old BALB/c nude mice with Cal27-vector as a control group. Bioluminescence imaging was used to examine lung metastasis, and H&E staining were performed to confirm lung metastasis nodules. Bioluminescence imaging results showed that MFAP5 overexpression can significantly increase lung metastasis burden (Figure 3A, P<0.01). This finding was verified by gross specimen and H&E staining (Figure 3B). Lung of Cal27-MFAP5 group had a higher amount of tumor node metastasis. The stained slice showed that the majority of lung tissue in MFAP5 group has been replaced by tumor cells. The results above proved that MFAP5 can facilitate metastasis in vivo.
Overexpressed MFAP5 promotes migration and invasion on HNSCC cell lines. (A) Relative mRNA expression of MFAP5 in Cal27 and HN30 transfected with MFAP5 and vector (**P<0.01). (B) The migration assay was performed to testify the migration ability of Cal27 and HN30 transfected with MFAP5 or negative control lentivirus (**P<0.01). (C) The wound healing assay was performed to testify the migration ability of Cal27 and HN30 transfected with MFAP5 or negative control lentivirus (**P<0.01). (D) The invasion assay was performed to testify the invasion ability of Cal27 and HN30 transfected with MFAP5 or negative control lentivirus (**P<0.01).
Overexpressed MFAP5 facilitates lung metastasis in vivo. (A) Bioluminescence imaging showed MFAP5 overexpression significantly increased lung metastasis burden (**P<0.01). (B) Gross specimen and H&E staining are shown (×100).
Western blot was performed to detect the protein level of Cal27 and HN30 transfected with MFAP5 or negative control lentivirus. The expression of MMP9, MMP2, vimentin, snail and p-AKT/AKT are significant higher along with MFAP5 (**P<0.01).
In accord with clinical observation, the results of in vivo and in vitro studies showed that MFAP5 promoted the migration and invasion of HNSCC. Combining with the fact that MFAP5 enhanced the expression of snail, we assumed that MFAP5 promotes tumor metastasis by activate the EMT program. To test this hypothesis, we firstly explored the protein level of MMP2, MMP9, vimentin and snail in HNSCC cells transfected with MFAP5 or vector. The results revealed that MFAP5 overexpression increased the level of these epithelium proteins (Figure 4). As a critical regulator of cell growth and migration, AKT signaling pathway was then detected to find out whether it was responsible for activating EMT program. The ratio of p-AKT/AKT in MFAP5 transfected cells was striking higher than control set (P<0.01, Figure 4). These results indicated that AKT phosphorylated by MFAP5 transported into nucleus, and activated snail to promote EMT program.
To further prove the effect of AKT in this process, MK2206 (S1078, Selleck Chemicals, USA) was applied to inhibited the phosphorylation of AKT. Western blot showed that it could markedly reduce the expression of p-AKT (P<0.01, Figure 5A) in MFAP5 transfected cells, the level of MMP2, MMP9, vimentin and snail was declined along with it (P<0.01, Figure 5A). Cell invasion and migration ability which enhanced by MFAP5 were also inhibited by MK2206 (P<0.01, Figure 5B, 5C, 5D).
Eighty-four tissue samples were performed immunohistochemical staining to determine the expression of MFAP5 in HNSCC. In consistent with our previous study, MFAP5 has a high expression inside HNSCC tumor tissue (Figure 6A). Combining with the clinical data of patients, we also discovered that MFAP5 expression was related with advanced stage and cervical lymph node metastasis of HNSCC (P<0.01, Figure 6B), which are important prognostic indicators. However, age, sex, site and pathologic grade were not related with MFAP5 expression level (Table 1). These results were further validated by The Cancer Genome Atlas (TCGA) dataset. Patients with overexpression of MFAP5 have a significant worse prognosis compared with low-expression set (P=0.013, Figure 6C). Besides, correlation analysis from TCGA dataset revealed that MFAP5 expression was correlated with MMP2, MMP9, vimentin, snail, AKT and HIF-1α which were consistent with our findings (Figure 6D). In situ staining of tissue samples indicated that high expression of MFAP5 could led to a high level of vimentin (P<0.01, Figure 6E). The results from tissue samples and dataset further demonstrated that MFAP5 promoted EMT program via AKT pathway in HNSCC.
The EMT program enhanced by MFAP5 could be reversed by MK2206. (A) The protein level of MMP9, snail, vimentin and p-AKT/AKT was reduced after MK2206 was applied to Cal27-MFAP5 and HN30-MFAP5 (**P<0.01) (B) Wound healing assay was performed to Cal27-MFAP5 and HN30-MFAP5 with or without MK2206 (**P<0.01). (C) Migration assay was performed to Cal27-MFAP5 and HN30-MFAP5 with or without MK2206 (**P<0.01). (D) Invasion assay was performed to Cal27-MFAP5 and HN30-MFAP5 with or without MK2206 (**P<0.01).
Baseline data of 84 patients enrolled
Variable | No. (%) | Low level | High level | P | |
---|---|---|---|---|---|
No. (%) | No. (%) | ||||
Age | 0.382 | ||||
<60 | 40 (47.6%) | 18 (41.9%) | 22 (53.7%) | ||
≥60 | 44 (52.4%) | 25 (58.1%) | 19 (46.3%) | ||
Sex | 0.279 | ||||
Male | 48 (57.1%) | 22 (51.2%) | 26 (63.4%) | ||
Female | 36 (42.9%) | 21 (48.8%) | 15 (36.6%) | ||
Site | 0.886 | ||||
Tongue | 37 (44.0%) | 18 (41.9%) | 19 (46.3%) | ||
Gingival | 13 (15.5%) | 7 (16.3%) | 6 (14.6%) | ||
Buccal mucosa | 15 (17.9%) | 7 (16.3%) | 8 (19.5%) | ||
Floor of the mouth | 10 (11.9%) | 6 (14.0%) | 4 (9.8%) | ||
Hard palate | 5 (6.0%) | 2 (4.7%) | 3 (7.3%) | ||
Lip | 4 (4.8%) | 3 (7.0%) | 1 (2.4%) | ||
TNM stage | |||||
Early stage | 37 (44.0%) | 28 (65.1%) | 9 (22.0%) | <0.01 | |
Advanced stage | 47 (56.0%) | 15 (34.9%) | 32 (78.0%) | ||
pN stage | |||||
N0 | 51 (60.7%) | 31 (72.1%) | 20 (48.8%) | 0.044 | |
N+ | 33 (39.3%) | 12 (27.9%) | 21 (51.2%) | ||
Pathology grade | 0.377 | ||||
Well-differentiated | 36 (42.9%) | 21 (48.8%) | 15 (36.6%) | ||
Moderate-differentiated | 32 (38.1%) | 16 (37.2%) | 16 (39.0%) | ||
Poorly-differentiated | 16 (19.0%) | 6 (14.0%) | 10 (24.4%) |
HNSCC as a common cancer can elicit both physical and mental damage in patients. Given that the long-term survival of HNSCC remains poor, an effective biomarker is imperative, especially for metastasis [24, 25]. As many studies suggest, hypoxia is a universal phenomenon in tumor microenvironment and it makes a major contribution to metastasis. EMT program is also believed to have an important role in initiate metastasis [26], but the molecular mechanism of EMT in HNSCC remains unclear. Our previous study has already demonstrated that overexpression of MFAP5 significantly correlated with cervical lymphatic metastasis and prognosis in HNSCC patients [15]. In the current study, we demonstrated that MFAP5 plays a critical role in hypoxia induced EMT program.
The relationship between MFAP5 and poor prognosis has been proven in many cancers as well as HNSCC [27-29]. In addition, we demonstrated that MFAP5 was also correlated with advanced stage and metastasis in this study. As a common phenomenon in tumor, EMT process is believed to have great impact on metastasis. EMT process provides tumor cell the ability to elude adhesion by decompose tumor stroma and change cellular morphology. Those evidences give us a hint that MFAP5 may promote metastasis by enhance the expression on phenotypic protein of EMT. Our results proved this hypothesis. MMP2, MMP9 and vimentin have a markedly higher expression in MFAP5 transfected cells, and tissue samples verified this finding.
Overexpression of MFAP5 can be observed in HNSCC and is associated with aggressive clinical features, poor outcome and EMT-related proteins. (A) Overexpression of MFAP5 can be observed in HNSCC. (B) MFAP5 expression is related with advanced stage (P<0.01) and cervical lymph node metastasis (P=0.04). (C) TCGA data shows high level of MFAP5 lead to poor prognosis (P=0.013). (D) Correlation analysis of relative mRNA expression shows MFAP5 is associated with EMT-related proteins. (E)The correlation analysis of immunohistochemistry intensity for vimentin and MFAP5 in 84 patients' tissue sample (r=0.399, P<0.01).
Hypoxia is another important factor for metastasis yet the correlation of MFAP5 and hypoxia is rarely reported. As the indicator and product of hypoxia environment, the expression of HIF-1α increase the extravasation of cancer cell and recruitment of circulating tumor cell. Nonetheless, the underlying mechanism remains unclear. Most previous studies claimed that MFAP5 is majorly secreted by stroma cells like cancer-associated fibroblasts (CAFs). Our research demonstrated for the first time that this lack oxygen environment could stimulate tumor cell to secret MFAP5. This finding suggests that MFAP5 is an important intermediate in hypoxia leading to metastasis.
It has been proven that MFAP5 exerts its function by binding the RGD domain on cancer cell to αVβ3 integrin whereas the downstream is still diverse [30]. Leung et al. discovered that binding αVβ3 integrin could activate FAK/CREB signaling pathway and increase the expression of TNNC1 which would lead to poor prognosis [31]; Wu et al. claimed that MFAP5 promote EMT program in breast cancer by activated TGF-β/Notch pathway [32]. Our research proved that AKT pathway is a key downstream for MFAP5 in HNSCC. The activation of AKT has a huge impact on tumor growth, proliferation, migration and invasion [33]. Yamamoto et al. found that AKT pathway was closely related with lung cancer proliferation and the migration ability would significant inhibited by down regulate AKT in NSCLC cells [34]. Previous studies have nicely demonstrated its function for promoting tumor progression. However, in this study, further exploration showed that AKT enhances the malignant biological behavior of tumor by increases the expression of snail, which is a promotor of EMT progress. The over-expressed snail facilitates the expression of MMP2, MMP9 and vimentin, which leads to the enhancement of invasion and migration. Data from an independent cohort further proved this finding. This result not only explored the mechanism of MFAP5 in HNSCC, but also provided a new target for the future treatment and prognosis prediction.
However, current studies of MFAP5 are majorly focus on its impact for tumor cells and the critical role of tumor microenvironment is often overlooked. Tumor microenvironment can not only secrete proteins that directly affect tumor cells like MFAP5, but also influence the prognosis by constructing tumor matrix and tumor immunity. For this reason, fully understanding the functions of these proteins on tumor-associated-stromal cells, such as infiltrating lymphocytes, CAFs, may make a big contribution to future treatment and prognosis. Therefore, the impact of MFAP5 on tumor environment cells is a promising future direction.
For the first time, we linked hypoxia, MFAP5 and metastasis into one process and proved that MFAP5 played an important role in hypoxia induced tumor progress in HNSCC. However, there are still some unsolved problems that require future exploration. First, whether the AKT pathway is directly activated by αVβ3 integrin is still unclear. Second, after the stimulation of hypoxia and overexpression of MFAP5 in the first place, what is the feedback mechanism of cancer cell? Will the overexpressed MFAP5 inhibit or promote its further secretion? Lastly, the interaction between MFAP5 and other cytokines is still unclear. Therefore, further studies are still needed to explore the underlying mechanism and novel downstream of MFAP5. Nonetheless, the critical role of MFAP5 in HSNCC progression for its enhancement of cell migration and invasion is undoubted. The findings of this study nicely proved MFAP5 as a potential biomarker and therapeutic target for HNSCC. Drugs targeting MFAP5 may be an effective treatment in future clinic application.
In conclusion, our study observes that MFAP5 has a significant higher expression in HNSCC patients and is correlated with advanced stage and cervical lymphatic metastasis. We further demonstrate that hypoxia can induce the expression of MFAP5 in HNSCC cell, which then promotes cell migration and invasion through AKT pathway. Overall, HIF1α-MFAP5-EMT axis will be a very promising therapeutic target to abolish metastasis in HNSCC.
HNSCC: Head and neck squamous cell carcinoma; MFAP5: Microfibrillar-associated protein 5; MAGP2: Microfibril-associated glycoprotein 2; EMT: epithelial-mesenchymal transition; HIF-1α: Hypoxia-inducible factor-1α; DMEM: Dulbecco's modified Eagle's medium; PBS: phosphate buffered saline solution; SDS-PAGE: sodium dodecyl sulfate-polyacrylamide gel electrophoresis; PVDF: polyvinylidene fluoride; TCGA: The Cancer Genome Atlas; CAFs: cancer-associated fibroblasts.
This work was partially supported by National Natural Science Foundation of China (81602367), Science and Technology Commission of Shanghai Municipality (YDZX20173100004422), Shanghai Sailing Program (19YF1427000) and Shanghai Youth Medical Talents-Specialist Program.
The authors have declared that no competing interest exists.
1. Xu Q, Wang C, Li B, Kim K, Li J, Mao M. et al. The impact of age on oral squamous cell carcinoma: A longitudinal cohort study of 2,782 patients. Oral diseases. 2019;25:730-41
2. de Carvalho AC, Scapulatempo-Neto C, Maia DC, Evangelista AF, Morini MA, Carvalho AL. et al. Accuracy of microRNAs as markers for the detection of neck lymph node metastases in patients with head and neck squamous cell carcinoma. BMC medicine. 2015;13:108
3. Sobral LM, Sousa LO, Coletta RD, Cabral H, Greene LJ, Tajara EH. et al. Stable SET knockdown in head and neck squamous cell carcinoma promotes cell invasion and the mesenchymal-like phenotype in vitro, as well as necrosis, cisplatin sensitivity and lymph node metastasis in xenograft tumor models. Molecular cancer. 2014;13:32
4. Hedberg ML, Goh G, Chiosea SI, Bauman JE, Freilino ML, Zeng Y. et al. Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma. The Journal of clinical investigation. 2016;126:169-80
5. Hanssen E, Hew FH, Moore E, Gibson MA. MAGP-2 has multiple binding regions on fibrillins and has covalent periodic association with fibrillin-containing microfibrils. The Journal of biological chemistry. 2004;279:29185-94
6. Lemaire R, Bayle J, Mecham RP, Lafyatis R. Microfibril-associated MAGP-2 stimulates elastic fiber assembly. The Journal of biological chemistry. 2007;282:800-8
7. Vaittinen M, Kolehmainen M, Ryden M, Eskelinen M, Wabitsch M, Pihlajamaki J. et al. MFAP5 is related to obesity-associated adipose tissue and extracellular matrix remodeling and inflammation. Obesity. 2015;23:1371-8
8. Albig AR, Roy TG, Becenti DJ, Schiemann WP. Transcriptome analysis of endothelial cell gene expression induced by growth on matrigel matrices: identification and characterization of MAGP-2 and lumican as novel regulators of angiogenesis. Angiogenesis. 2007;10:197-216
9. Spivey KA, Banyard J. A prognostic gene signature in advanced ovarian cancer reveals a microfibril-associated protein (MAGP2) as a promoter of tumor cell survival and angiogenesis. Cell adhesion & migration. 2010;4:169-71
10. Milwid JM, Elman JS, Li M, Shen K, Manrai A, Gabow A. et al. Enriched protein screening of human bone marrow mesenchymal stromal cell secretions reveals MFAP5 and PENK as novel IL-10 modulators. Molecular therapy. 2014;22:999-1007
11. Mok SC, Bonome T, Vathipadiekal V, Bell A, Johnson ME, Wong KK. et al. A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2. Cancer cell. 2009;16:521-32
12. Li Q, Zhang Y, Jiang Q. MFAP5 suppression inhibits migration/invasion, regulates cell cycle and induces apoptosis via promoting ROS production in cervical cancer. Biochemical and biophysical research communications. 2018;507:51-8
13. Craft CS, Broekelmann TJ, Mecham RP. Microfibril-associated glycoproteins MAGP-1 and MAGP-2 in disease. Matrix biology. 2018;71-72:100-11
14. Combs MD, Knutsen RH, Broekelmann TJ, Toennies HM, Brett TJ, Miller CA. et al. Microfibril-associated glycoprotein 2 (MAGP2) loss of function has pleiotropic effects in vivo. The Journal of biological chemistry. 2013;288:28869-80
15. Yang X, Wu K, Li S, Hu L, Han J, Zhu D. et al. MFAP5 and TNNC1: Potential markers for predicting occult cervical lymphatic metastasis and prognosis in early stage tongue cancer. Oncotarget. 2017;8:2525-35
16. Song Z, Liu T, Chen J, Ge C, Zhao F, Zhu M. et al. HIF-1alpha-induced RIT1 promotes liver cancer growth and metastasis and its deficiency increases sensitivity to sorafenib. Cancer letters. 2019;460:96-107
17. Lu X, Kang Y. Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clinical cancer research. 2010;16:5928-35
18. Schito L, Semenza GL. Hypoxia-Inducible Factors: Master Regulators of Cancer Progression. Trends in cancer. 2016;2:758-70
19. Tsai IT, Kuo CC, Liou JP, Chang JY. Novel microtubule inhibitor MPT0B098 inhibits hypoxia-induced epithelial-to-mesenchymal transition in head and neck squamous cell carcinoma. Journal of biomedical science. 2018;25:28
20. Principe S, Mejia-Guerrero S, Ignatchenko V, Sinha A, Ignatchenko A, Shi W. et al. Proteomic Analysis of Cancer-Associated Fibroblasts Reveals a Paracrine Role for MFAP5 in Human Oral Tongue Squamous Cell Carcinoma. Journal of proteome research. 2018;17:2045-59
21. Jin S, Yang X, Li J, Yang W, Ma H, Zhang Z. p53-targeted lincRNA-p21 acts as a tumor suppressor by inhibiting JAK2/STAT3 signaling pathways in head and neck squamous cell carcinoma. Molecular cancer. 2019;18:38
22. Ma H, Jin S, Yang W, Zhou G, Zhao M, Fang S. et al. Interferon-alpha enhances the antitumour activity of EGFR-targeted therapies by upregulating RIG-I in head and neck squamous cell carcinoma. British journal of cancer. 2018;118:509-21
23. Li H, Wang X, Wen C, Huo Z, Wang W, Zhan Q. et al. Long noncoding RNA NORAD, a novel competing endogenous RNA, enhances the hypoxia-induced epithelial-mesenchymal transition to promote metastasis in pancreatic cancer. Molecular cancer. 2017;16:169
24. Yu B, Zhang Y, Wu K, Wang L, Jiang Y, Chen W. et al. CD147 promotes progression of head and neck squamous cell carcinoma via NF-kappa B signaling. Journal of cellular and molecular medicine. 2019;23:954-66
25. Ma H, Yang W, Zhang L, Liu S, Zhao M, Zhou G. et al. Interferon-alpha promotes immunosuppression through IFNAR1/STAT1 signalling in head and neck squamous cell carcinoma. British journal of cancer. 2019;120:317-30
26. Diepenbruck M, Christofori G. Epithelial-mesenchymal transition (EMT) and metastasis: yes, no, maybe? Current opinion in cell biology. 2016;43:7-13
27. Wu Z, Wang T, Fang M, Huang W, Sun Z, Xiao J. et al. MFAP5 promotes tumor progression and bone metastasis by regulating ERK/MMP signaling pathways in breast cancer. Biochemical and biophysical research communications. 2018;498:495-501
28. Chen Z, Yan X, Li K, Ling Y, Kang H. Stromal fibroblast-derived MFAP5 promotes the invasion and migration of breast cancer cells via Notch1/slug signaling. Clinical & translational oncology. 2019 [Epub ahead of print]
29. Dawoud MM, Abouelfadl D, Abdou AG, Elkhouly EAB. Immunohistochemical Expression of Microfibrillar-associated Protein 5 (MFAP5) in Invasive Breast Carcinoma of No Special Type. Applied immunohistochemistry & molecular morphology: AIMM. 2018 [Epub ahead of print]
30. Deford P, Brown K, Richards RL, King A, Newburn K, Westover K. et al. MAGP2 controls Notch via interactions with RGD binding integrins: Identification of a novel ECM-integrin-Notch signaling axis. Experimental cell research. 2016;341:84-91
31. Leung CS, Yeung TL, Yip KP, Pradeep S, Balasubramanian L, Liu J. et al. Calcium-dependent FAK/CREB/TNNC1 signalling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potential. Nature communications. 2014;5:5092
32. Wu Y, Wu P, Zhang Q, Chen W, Liu X, Zheng W. MFAP5 promotes basal-like breast cancer progression by activating the EMT program. Cell & bioscience. 2019;9:24
33. LoRusso PM. Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors. Journal of clinical oncology. 2016;34:3803-15
34. Yamamoto H, Shigematsu H, Nomura M, Lockwood WW, Sato M, Okumura N. et al. PIK3CA mutations and copy number gains in human lung cancers. Cancer research. 2008;68:6913-21
Corresponding authors: Xi Yang, Department of Oral Maxillofacial-Head and Neck Oncology, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, No 639, Zhizaoju Rd, Shanghai 200011, China. Tel: +86 021 23271699 5160; Fax: +86 021 63136856; E-mail: yangxi112015com. Hailong Ma, Department of Oral Maxillofacial-Head and Neck Oncology, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, No 639, Zhizaoju Rd, Shanghai 200011, China. Tel: +86 021 23271699 5160; Fax: +86 021 63136856 E-mail:mahl21edu.cn
Received 2019-7-6
Accepted 2019-11-20
Published 2020-1-14